NCT06212635 Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
| NCT ID | NCT06212635 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Stockholm |
| Condition | Hemostasis in Decompensated Liver Cirrhosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-12-02 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-12-02 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Eligibility Criteria
Inclusion Criteria: * Patients with decompensated liver cirrhosis * 18 years or older. * Healthy individuals 18 years or older will serve as controls. Exclusion Criteria: * • Extrahepatic malignancy or recurrence of such within the last year. * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion. * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies * Previous liver transplantation. * Transfusions the last 7 days. * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
Contact & Investigator
Maria Magnusson, MD, PhD
PRINCIPAL INVESTIGATOR
Region Stockholm, Karolinska Institute
Frequently Asked Questions
Who can join the NCT06212635 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemostasis in Decompensated Liver Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06212635 currently recruiting?
Yes, NCT06212635 is actively recruiting participants. Contact the research team at sanna.noren@regionstockholm.se for enrollment information.
Where is the NCT06212635 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT06212635 clinical trial?
NCT06212635 is sponsored by Region Stockholm. The principal investigator is Maria Magnusson, MD, PhD at Region Stockholm, Karolinska Institute. The trial plans to enroll 100 participants.